REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Antigen, Epitope, Or Other Immunospecific Immunoeffector (e.g., Immunospecific Vaccine, Immunospecific Stimulator Of Cell-mediated Immunity, Immunospecific Tolerogen, Immunospecific Immunosuppressor, Etc.) > Amino Acid Sequence Disclosed In Whole Or In Part; Or Conjugate, Complex, Or Fusion Protein Or Fusion Polypeptide Including The Same > Disclosed Amino Acid Sequence Derived From Bacterium (e.g., Mycoplasma, Anaplasma, Etc.) Disclosed Amino Acid Sequence Derived From Bacterium (e.g., Mycoplasma, Anaplasma, Etc.)Disclosed Amino Acid Sequence Derived From Bacterium (e.g., Mycoplasma, Anaplasma, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/02/07 - 20070178117 - Polyvalent chimeric ospc vaccinogen and diagnostic antigen A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian Borrelia infections. ... 08/02/07 - 20070178116 - Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof This invention provides isolated nucleic acids encoding polypeptides comprising amino acid sequences of streptococcal matrix adhesion (Ema) polypeptides. The invention provides nucleic acids encoding Group B streptococcal Ema polypeptides EmaA, EmaB, EmaC, EmaD and EmaE. The present invention provides isolated polypeptides comprising amino acid sequences of Group B streptococcal polypeptides ... 07/12/07 - 20070160624 - Anthrax and small pox replikins and methods of use Isolated peptides of the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01-107, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01-107 are disclosed. Also disclosed are isolated peptides of the Small ... 06/14/07 - 20070134264 - Helicobacter system and uses thereof Helicobacter based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, Helicobacter pylori vectors, vector plasmids and recombinant cells that include a sequence encoding a pharmacologically active molecule of interest useful in therapeutic treatments and/or vaccination against ... 06/14/07 - 20070134263 - Polypeptides for inducing a protective immune response against staphyloococcus aureus The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full length S. aureus polypeptide. The full-length polypeptide is referred to herein as full-length “sai-1”. A His-tagged derivative ... 06/07/07 - 20070128211 - Surface proteins of streptococcus pyogenes β-hemolytic streptococci polynucleotides, polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, and antibodies of these polypeptides are described. The polynucleotides, polypeptides, and antibodies of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing β-hemolytic streptococcal infection, and for detecting β-hemolytic streptococci ... 06/07/07 - 20070128210 - Surface proteins of streptococcus pyogenes β-hemolytic streptococci polynucleotides, polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, and antibodies of these polypeptides are described. The polynucleotides, polypeptides, and antibodies of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing β-hemolytic streptococcal infection, and for detecting β-hemolytic streptococci ... 05/31/07 - 20070122425 - Process for recombinant expression and purification of antimicrobial peptides using periplasmic targeting signals as precipitable hydrophobic tags A process was developed for expressing antimicrobial peptides in a recombinant host cell that eliminates host cell toxicity and antimicrobial peptide degradation, as well as providing a process for rapid purification. Fusion proteins comprising a periplasmic targeting signal, cleavage site, and antimicrobial peptides provide the basis for this process which ... 05/24/07 - 20070116712 - Novel streptococcus antigens Streptococcus proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection. ... 05/24/07 - 20070116711 - Pertussis antigens and use thereof in vaccination The invention provides BASB232 polypeptides and polynucleotides encoding BASB232 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. The invention further provides immunogenic compositions comprising a plurality of antigens selected from at least two different categories of antigen, having different functions ... 05/17/07 - 20070110766 - Proteinase k resistant surface protein of neisseria meningitidis The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been ... 05/17/07 - 20070110765 - Helicobacter pylori bacterioferritin A nucleic acid sequence encoding all or part of an 18-19 kDa Helicobater pylori protein is described to which immunoreactivity is detected in H. pylori negative individuals. A process for the production of a recombinant form of this protein and its use, particularly as a vaccine to provide immunological protection ... 05/17/07 - 20070110764 - Proteins with repetitive bacterial-ig-like (big) domains present in leptospira species The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 ... 05/17/07 - 20070110763 - Polypeptides of streptococcus pyogenes The present invention relates to polypeptides of S. pyogenes which may be useful to prevent, diagnose and/or treat S. pyogenes infections. ... 05/17/07 - 20070110762 - Process for preparing polysaccharide-protein conjugate vaccines Methods for the manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency. Simplified purification processes can be employed to separate the ... 05/17/07 - 20070110761 - Protein purification means Described is a novel purification tag, SNUT, based on the gene product of a sortase gene, in particular the srtA gene of Staphylococcus aureus and uses thereof. Also provided are expression constructs comprising DNA enoding the tag for the production of recombinant polypeptides. The tag can be used in methods ... 05/03/07 - 20070098737 - Streptococcal streptolysin s vaccines Provided are streptolysin S (SLS) polypeptides, peptides, and variants thereof, antibodies directed thereto, and isolated nucleic acids encoding such proteins. In one embodiment, a method is provided wherein a synthetic peptide of SLS is used to elicit an immune response specific for SLS in a subject to treat or prevent ... 04/26/07 - 20070092533 - Method of preventing t cell-mediated responses by the use of the major histocompatibility complex class ii analog protein (map protein) from staphylococcus aureus A method of immunomodulating the T cell response in Staphylococcal bacteria is provided wherein an effective amount of the Map protein from Staphylococcus aureus is administered to a host to prevent or suppress the T cell response. The present method may be utilized with either the Map protein or an ... 04/19/07 - 20070087011 - Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides. ... 04/12/07 - 20070082007 - Novel immunogenic compositions for the prevention and treatment of meningococcal disease The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of ... 04/12/07 - 20070082006 - Novel immunogenic compositions for the prevention and treatment of meningococcal disease The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of ... 04/12/07 - 20070082005 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting ... 04/05/07 - 20070077256 - Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic ... 03/29/07 - 20070071768 - Use of rip in treating staphylococcus aureus infections The present composition combines an RNAIII-inhibiting peptide (RIP) with an antimicrobial peptide, such as a cathelicidin, that is capable of binding and neutralizing lipidic and polyanionic components of bacterial cell envelope. In another embodiment, the RIP is combined with an antibiotic, with or without an antimicrobial peptide. The present composition ... 03/08/07 - 20070053927 - Chlamydia pneumoniae polynucleotides and uses thereof The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of Chlamydia pneumoniae, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors ... 03/08/07 - 20070053926 - Antigenic neisserial peptides WO99/24578 discloses a large number of proteins from Neisseria meningitidis and Neisseria gonorrhoeae. The present invention relates to fragments of those proteins which comprise at least one antigenic determinant. Homologous sequences and proteins comprising these fragments are also disclosed. ... 03/08/07 - 20070053925 - Staphylococcus aureus efb protein and c3 binding region which inhibit complement activation The Efb protein from Staphylococcus aureus has now been shown to have the ability to bind to the C3 protein which is a crucial component in the activation of complement, and a specific C3 binding region has been located at the C-terminal end of the Efb protein. Isolated proteins and ... 03/08/07 - 20070053924 - Conserved and specific streptococcal genomes The invention relates to polynucleotides which are conserved or specific to one or more species of Streptococcus, Streptococcus species serotypes, and/or serotype isolates. In particular, the invention relates to polynucleotides from Streptococcus which are conserved or specific to one or more of the species of S. pneumoniae (“pneumococcus” or “S. ... 02/22/07 - 20070041991 - Babesia vaccines The invention relates to Babesia proteins of a 28 kDa protein family and to immunogenic fragments of such proteins, to nucleic acids encoding such proteins or fragments, to cDNA fragments, recombinant DNA molecules, live recombinant carriers, or host cells comprising such nucleic acids, to vaccines, to methods for the preparation ... 02/15/07 - 20070036816 - Tuberculosis antigen detection assays and vaccines The present invention relates to isolated Tuberculosis (TB) antigens that are useful in therapeutic and vaccine compositions for stimulating a TB specific immunological response. The identified antigens are also useful in diagnostic assays to determine the presence of active TB in an individual. Accordingly, the present invention includes polypeptide molecules, ... 02/15/07 - 20070036815 - Ricin-like toxins for treatment of cancer The present invention provides a protein having chain of a ricin-like toxin, a B chain of a ricin-like toxin and a novel heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a specific protease such as those found in ... 02/15/07 - 20070036814 - S. aureus fibrinogen binding protein gene The isolation of genes and proteins from Staphylococcus aureus is provided, and the nucleic acids coding for specific regions of the S. aureus CIfA protein are described. The nucleic acids encode proteins that can be useful as vaccines or in pharmaceutical compositions for application to prevent infection, promotion of wound ... 02/08/07 - 20070031447 - Method of isolating biologically active fraction containing clinically acceptable native s-lipopolysaccharides obtained from bacteria producing endotoxic lipopolysaccharides A biologically active fraction (BAF) is presented containing mainly S-lipopolysaccharide (LPS) from gram-negative bacteria producing endotoxic LPSs. These fractions are characterized in that in the lipid A of S-LPS the mole ratio of D-glucosamine and β-hydroxy acids selected from the group comprising β-hydroxydecanoic, β-hydroxydodecanoic, β-hydroxytetradecanoic, β-hydroxyhexadecanoic, is approximately 2:1-4, and ... 02/01/07 - 20070026012 - Compositions and methods for monitoring and altering protein folding and solubility The present invention relates to the fields of microbiology, molecular biology and protein biochemistry. More particularly, it relates to compositions and methods for analyzing and altering (e.g., enhancing or inhibiting) protein folding and solubility. ... 02/01/07 - 20070026011 - Sdr proteins from staphylococcus capitis and their use in preventing and treating infections An isolated and/or purified Sdr surface protein from S. capitis and nucleic acids encoding them are provided which includes the SdrX protein which possesses collagen binding activites and the SdrZL protein which possesses SdrZ-like properties. The Sdr surface proteins from S. capitis can be used in pharmaceutical compositions to treat ... 02/01/07 - 20070026010 - Purification process for bacterial cytolysin The present invention relates to a method for purifying bacterial cytolysins such as pneumococcal pneumolysin. A single chromatography step produces excellent purification of the cytolysin by binding soluble aggregated cytolysin to a hydrophobic interaction chromatography material in the presence of detergent and high salt. ... 01/25/07 - 20070020286 - Recombinant constructs of borrelia burgdorferi Novel chimeric nucleic acids, encoding chimeric Borrelia proteins comprising OspC or an antigenic fragment thereof and OspA or an antigenic fragment thereof, are disclosed. Chimeric proteins encoded by the nucleic acid sequences are also disclosed. The chimeric proteins are useful as vaccine immunogens against Lyme borreliosis, as well as for ... 01/25/07 - 20070020285 - Novel peptide compositions and the use thereof, in particular, in the preparation of active pharmaceutical compositions against the hepatitis c virus The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID N° 1, a peptide B having at least ... 01/11/07 - 20070009546 - Purified polypeptides from streptococcus pneumoniae The invention provides novel polypeptides and polynucleotides encoding such polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing such polypeptides to screen for antibacterial compounds. ... 01/11/07 - 20070009545 - Mycoplasma subunit vaccine The present invention relates i.a. to vaccines for combating Mycoplasma infection, to mycoplasmal L-α-glycerophosphate oxidase for use in such vaccines, to the use of mycoplasmal L-α-glycerophosphate oxidase for the manufacturing of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the discrimination of animals ... 01/04/07 - 20070003569 - 32-kda protein derived from mycobacterium tuberculosis and related peptides The invention relates to recombinant polypeptides and peptides and particularly to the polypeptide containing in its polypeptidic chain the following amino acid sequence: the one extending from the extremity constituted by nucleotide at position (1) to the extremity constituted by nucleotide at position (194) represented in FIG. 4a and FIG. ... 01/04/07 - 20070003568 - Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof The present invention relates to secreted Chlamydia polypeptides, which may be expressed by a Gram-negative bacterial strain and secreted by the type III secretion pathway of said bacterial strain. The present invention also relates to polynucleotides coding for these polypeptides, as well as to the therapeutic and vaccination uses of ... 01/04/07 - 20070003567 - Composition and methods for enhancing immunogenecity of antigens Compositions and methods for enhancing the immunogenicity of an antigen via fusion to a non-hemolytic truncated form of listeriolysin or a PEST-like amino acid sequence derived from a prokaryotic organism are provided. ... 12/28/06 - 20060292169 - Fusion proteins of mycobacterium tuberculosis antigens and their uses The present invention relates to fusion proteins containing at least two Mycobacterium tuberculosis antigens. In particular, it relates to bi-fusion proteins which contain two individual M. tuberculosis antigens, tri-fusion proteins which contain three M. tuberculosis antigens, tetra-fusion proteins which contain four M. tuberculosis antigens, and penta-fusion proteins which contain five ... 12/28/06 - 20060292168 - Methylated heparin-binding hemagglutinin recombinant mycobacterial antigen, preparation method and immunogenic compositions comprising same The invention concerns a methylated immunogenic recombinant peptide sequence comprising mycobacterial heparin-binding hemagglutinin. The invention also concerns chemical and enzymatic methods for preparing such a sequence, the sequence being previously produced in a non-methylated recombinant form then methylated by post-translational modification. The invention further concerns recombinant tools, vectors and host ... 12/21/06 - 20060286119 - Compositions and methods for treatment of chronic and infectious diseases The present invention generally features therapeutic and diagnostic compositions and methods for increasing or decreasing the binding of a lysozyme polypeptide to a Treponema pallidum P17 polypeptide (Tp17) or a Tp17-like polypeptide. More particularly, the invention relates to compositions and methods for detecting, treating, or preventing a pathogen infection or ... 12/21/06 - 20060286118 - Lawsonia intracllularis subunit vaccine The present invention relates to nucleic acid sequences encoding novel Lawsonia intracelluaris proteins. It furthermore relates to DNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Also it relates to host cells comprising such nucleic acid sequences, DNA fragments, recombinant DNA molecules and live recombinant carriers. Moreover, ... 12/07/06 - 20060275318 - Surface protein of leptospira The invention relates to Leptospiral surface proteins, and the nucleic acid molecules which encode them. Various uses are described, including immunoprophylactic, diagnostic and therapeutic methods. ... 12/07/06 - 20060275317 - Vaccine compositions for prevention of chronic and infectious diseases The present invention generally features therapeutic and diagnostic compositions and methods for increasing or decreasing the binding of a lysozyme polypeptide to a Treponema pallidum P17 polypeptide (Tp17) or a Tp17-like polypeptide. More particularly, the invention relates to compositions and methods for detecting, treating, or preventing a pathogen infection or ... 12/07/06 - 20060275316 - Modulation of cxcr4 and related methods and compositions A method for inhibiting the SDF1-CXCR4 signaling pathway in a subject, comprising administering to the subject an effective amount of a Beta Defensin (BD)-inducing agent. The BD-inducing agent may be a Fusobacterium associated defensin inducer (FAD-I) polypeptide or a double stranded RNA analog. ... 12/07/06 - 20060275315 - Nucleic acids and proteins from streptococcus groups a & b The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. ... 11/30/06 - 20060269564 - Yersinia spp. polypeptides and methods of use The present invention provides isolated polypeptides isolatable from a Yersinia spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides. ... 11/30/06 - 20060269563 - Mutant forms of meningococcal adp-ribosylating toxin NMB1343 is an ADP-ribosylating toxin from Neisseria meningitidis. The invention provides a mutant-toxin having a substitution at one or more of amino Glu-109, Glu-111 or Glu-120. The mutations(s) is/are preferably Glu to Asp. The protein of the invention preferably has reduced or eliminated ADP-ribosyltransferase and/or NAD-glycohydrolase activity relative to the ... 11/16/06 - 20060257421 - Pneumolysin derivatives The present invention relates to vaccines against bacterial pathogens. In particular, the invention relates to modified epitopes of bacterial antigens. ... 11/09/06 - 20060251671 - Haemophilus influenza outer membrane protein and use thereof in vaccination This invention relates to recombinant bacterial outer membrane proteins comprising one or more LB1(f) peptides from surface-exposed loop 3 of MOMP P5 of non-typeable H. influenzae. Polynucleotides encoding these recombinant proteins are also covered. The invention also relates to a method of isolating the recombinant proteins and a vaccine composition ... 11/09/06 - 20060251670 - Multiple variants of meningococcal protein nmb1870 Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. ... 10/26/06 - 20060240035 - Vmp-like sequences of pathogenic borrelia species and strains The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. ... 10/19/06 - 20060233826 - Porin b (porb) as a therapeutic target for prevention and treatment of infection by chlamydia The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which ... 10/19/06 - 20060233825 - C. perfringens alpha toxoid vaccine The present invention describes vaccines that comprise C. perfringens Type alpha toxoids, antigenic fragments thereof, inactivated antigenic fragments of C. perfringens Type alpha toxins, or any combination thereof. The present invention further describes methods of using with these vaccines to protect animals against clostridial diseases. The present invention also describes ... 10/19/06 - 20060233824 - Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides. ... 10/19/06 - 20060233823 - Nucleic acids and proteins of the mycoplasma hyopneumoniae mhp3 gene and uses thereof The present invention relates to mhp3 nucleic acids and proteins encoded by the foregoing. The present invention further relates to novel apoprotein antigens encoded by mhp3 for use in vaccines to prevent and treat diseases caused by infection with Mycoplasma hyopneumoniae. The invention further relates to methods for the recombinant ... 09/28/06 - 20060216308 - Immunisation against chlamydia trachomatis The present invention provides antigenic proteins of Chlamydia trachomatis. The proteins of the present invention are useful for eliciting an immune response to Chlamydia in a patient. For example, an effective amount of protein of the present invention or fraction thereof may be administered to a patient for eliciting a ... 09/28/06 - 20060216307 - Vaccine composition The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the ... 09/21/06 - 20060210582 - Nucleic acids and proteins from streptococcus groups a & b The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics. ... 09/21/06 - 20060210581 - Nucleic acids and proteins from streptococcus groups a & b The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics. ... 09/21/06 - 20060210580 - Nucleic acids and proteins from streptococcus groups a & b The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics. ... 09/21/06 - 20060210579 - Nucleic acids and proteins from streptococcus groups a & b The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics. ... 09/21/06 - 20060210578 - Immunogenic polypeptide isolated from mycobacterium avium subspecies paratuberculosis and uses therof The present invention relates to an immunogenic polypeptide isolated from Mycobacterium avium subspecies paratuberculosis and variants of the polypeptide. The polypeptide and variants may be used in vaccines against Johne's disease and in methods for detection of the disease. Antibodies against the polypeptide or variants may be used in diagnostic ... 09/14/06 - 20060204515 - Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi Unique compounds that can be used for inducing an immune response to Borrelia burgdorferi in a subject by administering a therapeutically effective amount of the glycolipid to the subject. Such administration is particularly useful for preventing or treating Lyme disease in a subject. The compounds(s), and therapeutically acceptable salts thereof, ... 09/14/06 - 20060204514 - Expression of hydrophobic proteins Methods are disclosed for the design of non-native (i.e. heterologous) polypeptides comprising a proportion of hydrophobic amino acids which have an increased probability of being efficiently expressed in an expression system such as a bacterial host (e.g. E. coli). The methods involve identifying one or more hydrophobic peptide sequences within ... 09/07/06 - 20060198852 - Collagen-binding mscramms of bacillus anthracis and uses therefor The present invention provides cell wall anchored proteins of Bacillus anthracis representative of the MSCRAMM family of proteins and DNAs encoding the same. Also provided are collagen-binding peptides comprising the collagen-binding region A of the cell wall anchored proteins and DNAs encoding these peptides. Further provided are pharmaceutical compositions and ... 08/24/06 - 20060188516 - Chlamydia trachomatis antigens The present invention relates to antigenic proteins from Chlamydia trachomatis. A method for inducing an immune response with an immunogenic Chlamydia protein is provided in which an effective amount of an immunogenic Chlamydia protein is administered to a subject. In one example, the immunogenic Chlamydia protein has a molecular weight ... 08/24/06 - 20060188515 - Polypeptides for inducing a protective immune response against staphylococcus aureus The present invention features hybrid polypeptides providing ORF0657n and ORFO190 epitopes, nucleic acid encoding for the different polypeptides, and a method for evaluating the ability of an immunogen to produce a protective immune response against Staphylococcus infection. ORF0657n and ORF0190 are both S. aureus proteins. ... 08/24/06 - 20060188514 - Products specific to pathogenic strains and their use as vaccines and in immunotherapy The invention relates to isolated antigenic polypeptides obtainable by a process comprising the steps of: 1—selecting on the basis of sequence analysis those of the polypeptides which are either located in the outermembrane or secreted by the bacteria, 2—identifying the genes coding for said polypeptides which are conserved in B2/D ... 08/17/06 - 20060182759 - Novel proteins in enteroaggregative escherichia coli (eaec) useful for diagnosis and therapy of eaec infections Novel proteins and their corresponding nucleotide sequences in enteroaggregative Escherichia coli (EAEC) are provided. In particular, Aap and the five gene cluster (aat) of the AA probe region of the pAA plasmid of EAEC 042 have been identified, sequenced, and further characterized. The use of these novel proteins and their ... 08/17/06 - 20060182758 - Novel proteins in enteroaggregative escherichia coli (eaec) useful for diagnosis and therapy of eaec infections Novel proteins and their corresponding nucleotide sequences in enteroaggregative Escherichia coli (EAEC) are provided. In particular, Aap and the five gene cluster (aat) of the AA probe region of the pAA plasmid of EAEC 042 have been identified, sequenced, and further characterized. The use of these novel proteins and their ... 08/17/06 - 20060182757 - Novel proteins in enteroaggregative escherichia coli (eaec) useful for diagnosis and therapy of eaec infections Novel proteins and their corresponding nucleotide sequences in enteroaggregative Escherichia coli (EAEC) are provided. In particular, Aap and the five gene cluster (aat) of the AA probe region of the pAA plasmid of EAEC 042 have been identified, sequenced, and further characterized. The use of these novel proteins and their ... 08/17/06 - 20060182756 - Groups of borrelia burgdorferi and borrelia afzelii that cause lyme disease in humans The present invention is drawn to an immunogenic composition comprising OspC polypeptides from Lyme Disease causing Borrelia. In one embodiment, the immunogenic composition of the present invention comprises at least one OspC polypeptide or immunogenic fragment thereof from each of Borrelia burgdorferi OspC families A, B, I and K. In ... 08/10/06 - 20060177466 - Novel proteins in enteroaggregative escherichia coli (eaec) useful for diagnosis and therapy of eaec infections Novel proteins and their corresponding nucleotide sequences in enteroaggregative Escherichia coli (EAEC) are provided. In particular, Aap and the five gene cluster (aat) of the AA probe region of the pAA plasmid of EAEC 042 have been identified, sequenced, and further characterized. The use of these novel proteins and their ... 08/10/06 - 20060177465 - Streptococcus antigens Streptococcus polypeptides and polynucleotides encoding them are disclosed. Said polypeptides may be useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection. ... 08/10/06 - 20060177464 - Methods and compositions involving lcrv proteins The present invention concerns methods and compositions involving modified LcrV proteins from Yersinia bacteria. These methods and compositions can be employed to invoke an immune response in a subject against the bacteria, while not suppressing the immune system as much as the native LcrV protein. In certain embodiments, the present ... 08/10/06 - 20060177463 - Compositions and methods for inhibiting h. pylori adhesion and infection The present invention provides compositions and methods for treating or preventing bacterial infections. Also provide by the invention are genetically modified cell expressing Lewisb carbohydrate epitope. ... 08/10/06 - 20060177462 - Polypeptides for inducing a protective immune response against staphylococcus aureus The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1, uses of such polypeptides, and expression systems for producing such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full length <i>S. aureus</i> polypeptide. The full-length polypeptide is referred to herein ... 08/03/06 - 20060171957 - Polypeptide-vaccines for broad protetion against hypervirulent meningococcal lineages A small number of defined antigens can provide broad protection against meningococcal infection, and the invention provides a composition which, after administration to a subject, is able to induce an antibody response in that subject, wherein the antibody response is bactericidal against two or three of hypervirulent lineages A4, ET ... 07/27/06 - 20060165718 - Immunizing compositions and methods of use The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions. ... 07/27/06 - 20060165717 - Dcchol in newborns The present invention involves the use of DCchol for preparing a vaccine composition intended to be administered to newborns. ... 07/27/06 - 20060165716 - Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group B Streptococcus serotypes and isolates. The adhesin islands are thought to encode surface proteins which are important in the bacteria's virulence. Thus, the adhesin island proteins of the invention may ... 07/20/06 - 20060159697 - Modified bordetella adenylate cyclase comprising or lacking cd11b/cd18 interaction domain and uses thereof The invention relates to modified Bordetella adenylate cyclase toxins which are deficient for CD11b/CD18 binding and to their use in the preparation of pharmaceutical composition for the treatment of whooping cough and/or for the protection against Bordetella infection. The invention also relates to specific fragments of Bordetella adenylate cyclase comprising ... 07/06/06 - 20060147462 - Compounds from moraxella catarrhalis This invention provides BASB020 polypeptides and polynucleotides encoding BASB020 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. ... 07/06/06 - 20060147461 - Use of clya hemolysin for excretion of proteins The disclosure below provides a protein export system for efficiently producing recombinant protein from a host cell. In a preferred embodiment, the protein export system utilizes protein export machinery endogenous to the host bacterium into which the protein export system vector is introduced. ... 06/29/06 - 20060140972 - Staphylococcus saprophyticus nucleic acids and polypeptides Isolated nucleic acid molecules which encode proteins from Staphylococcus saprophyticus are described. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing nucleic acid molecules, and host cells into which the expression vectors have been introduced. The invention still further provides isolated proteins, mutated proteins, fusion proteins, antigenic ... 06/29/06 - 20060140971 - Cell surface expression vector of sars virus antigen and microorganisms transformed thereby The present invention relates to a surface expression vector of SARS coronavirus antigen containing a gene encoding an antigen of SARS inducing coronavirus and any one or two or more of genes pgsB, pgsC and pgsA encoding poly-gamma-glutamic acid synthase complex, a microorganism transformed by the surface expression vector, and ... 06/15/06 - 20060127411 - Immune -modulating peptide made of s.aureus enterotoxin b The invention relates particularly to peptides which are specifically capable of binding IgE antibodies and can be obtained from naturally occurring S. aureus enterotoxin B (SEB), for example. The immune-modulating properties thereof are substantially different from those of bacterial SEB. Surprisingly, the inventive peptides do not induce proliferation of T ... 06/08/06 - 20060121050 - Fusion protein comprising bacillus calmette guerin heat shock protein 65 and the epitope of human prostate specific antigen Certain embodiments of the invention provide a fusion protein comprising Bacillus Calmette Guérin heat shock protein 65 and one to five copies of the epitope of human prostate specific antigen. The fusion protein provided by certain embodiments is therapeutic and/or preventive to human prostate cancer. Certain embodiments also provide the ... 06/01/06 - 20060115491 - Method to provide bacterial ghosts with antigens Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating the cell-wall material with a solution capable of removing a cell-wall component such as a ... 06/01/06 - 20060115490 - Staphylococcus aureus proteins and nucleic acids The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics. ... 05/18/06 - 20060104990 - Outer surface proteins, their genes, and their use According to the present invention, a series of genes are identified in Group B Streptococcus, the products of which may be located on the outer surface of the organism. The genes, or functional fragments thereof, may be useful in the preparation of therapeutics, e.g. vaccines for the immunization of a ... 05/18/06 - 20060104989 - Essential novel bacterial polypeptides The present invention relates to polypeptide targets for pathogenic bacteria. The invention also provides biochemical and biophysical characteristics of those polypeptides. ... 05/11/06 - 20060099221 - Method of screening anti-mycobacterial molecules This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the ... 04/27/06 - 20060088546 - Antigens for raising an immune response against rickettsieae and ehrlichieae pathogens The present invention relates to the identification of polypeptides which are useful for raising an immune response against Ehrlichieae and Rickettsieae pathogens when administered into a subject. These polypeptides, and polynucleotides encoding therefor, can be used in various strategies for preventing or treating Ehrlichieae and Rickettsieae infections. ... 04/20/06 - 20060083753 - Fusobacterium polypeptides and methods of use The present invention provides isolated polypeptides isolatable from a Fusobacterium spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides. ... 04/20/06 - 20060083752 - Novel compounds This invention relates to newly identified Staphylococcal polynucleotides, polypeptides encoded by such polynucleotides, the uses of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides and recombinant host cells transformed with the polynucleotides. This invention also relates to inhibiting the biosynthesis or action of such ... 04/13/06 - 20060078566 - Antigen orf rv2430c and a method thereof The present invention relates to a PPE family antigenic protein Rv2430c of SEQ ID No. 1; a set of three high antigenic index peptides of SEQ ID Nos. 2 to 4; an antigenic ORF Rv2430c of SEQ ID No. 5 and lastly a method of inducing immune response against Mycobacterium ... 04/13/06 - 20060078565 - Nucleic acids and proteins from group b streptococcus Protein antigens from Group B Streptococcus are described, together with nucleic acid sequences encoding them. Their use in vaccines and screening methods are described. ... 04/06/06 - 20060073161 - Nucleic acid and amino acid sequences relating to bacteroides fragilis for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Bacteroides fragilis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting ... 03/30/06 - 20060067945 - Production of recombinant protein pap 31 for the diagnosis and prevention of bartonella bacilliformis infection The invention relates to a recombinant DNA and polypeptide sequence of an immuno-dominant phage particle associated protein from Bartonella bacilliformis. The recombinant protein is easily produced permitting the conduct of more accurate and rapid diagnositic assays for the detection of B. bacilliformis infection with reduced reagent and equipment requirements over ... 03/16/06 - 20060057155 - Adp-ribosylating bacterial toxins ADP-ribosylating toxins from Neisseria meningitidis, Streptomyces coelicolor, Mycoplasma pneumoniae, Salmonella typhimurium Salmonella paratyphi, and Streptococcus pyogenes are disclosed, together with mutant toxins and uses therefor. There is only a low level of sequence identity between these toxins and toxins such as cholera toxin and E. coli heat labile toxin. ... 03/09/06 - 20060051364 - Lutzomyia longipalpis polypeptides and methods of use Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing ... 03/09/06 - 20060051363 - Protein inducing cell death of helicobacter pylori The present invention revealed that the apoptosis-inducing protein of Helicobacter pylon is a protein complex composed by association of two kinds of proteins, which comprise a part of the amino acid sequence encoded by γ-glutamyl transferase gene (HP1118). The present invention is said protein and a vaccine comprising said protein. ... 03/09/06 - 20060051362 - Antigens for actinobacillus pleuropneumoniae and methods thereof The present invention is related to a DNA sequence of outer membrane proteins of Actinobacillus pleuropneumoniae expressed in a subject suffering from pleuropneumonia, the sequence coding for the receptor for the uptake of ferric hydroxamate FhuA as set forth in SEQ ID NO: 1 in Actinobacillus pleuropneumoniae, or any functional ... 03/09/06 - 20060051361 - Vaccine against streptococcus pneumoniae The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen from Streptococcus pneumoniae selected from the group consisting of PhtA, PhtD, PhtB, PhtE, SpsA, LytB, LytC, LytA, Sp125, Sp101, ... 02/23/06 - 20060039923 - Vaccine for preventing and treating porcine progressive atrophic rhinitis The present invention relates to an animal vaccine directed to progressive atrophic rhinitis (PAR), comprising at least two fragmens of recombinant subunit Pasteurella multocida toxins (rsPMT) capable of eliciting the production of antibodies against Pasteurella multocida associated with PAR, said fragments each having an amino acid sequence that substantially corresponds ... 02/23/06 - 20060039922 - Streptococcal heat shock proteins of the hsp60 family Methods and compositions comprising isolated nucleic acid molecules specific to Streptococcus pneumoniae and Streptococcus pyogenes, as well as vector constructs and isolated polypeptides specific to Streptococcus pneumoniae and Streptococcus pyogenes are provided. Such compositions and methods are useful for the diagnosis of Streptococcal infection and for generating an immune response ... 02/23/06 - 20060039921 - Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus The present invention relates to a method for potentiating a specific immune response to an antigen in a mammal in need thereof. The method comprises administering to the mammal an effective amount of Ov-ASP, or at least one subunit of Ov-ASP, and an antigenic moiety. ... 02/23/06 - 20060039920 - Orientia tsutsugamushi truncated recombinant outer membrane protein (r47) and (r56) vaccines diagnostics and therapeutics for scrub typhus and hiv infection A scrub typhus vaccine comprising truncated r47 protein and truncated r56 protein is disclosed. Vaccines composed of r56 protein variants are also disclosed. Methods of reducing HIV viral loads using r47 and r56 proteins and antibodies raised against r47 and r56 are also disclosed. ... 02/16/06 - 20060034863 - Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof The inventors have discovered that a CKβ8-1 truncation variant, CKβ8-1 (25-116), is a bifunctional ligand for two distinct GPCRs, chemokine receptor CCR1 and formyl peptide receptor like 1 (FPRL1). Hence, the inventors have discovered that, in addition to its functional activity on CCR1, CKβ8-1(25-116) is also a functional ligand for ... 02/16/06 - 20060034862 - Method for diagnosing early and late lyme borreliosis The present invention relates to a method for detecting Borrelia burgdorferi sensu lato infection or the presence of antibodies against Borrelia species in a body fluid from a suspected infected or vaccinated human or other mammal, to a diagnostic kit useful in said method and to an immunoassay method for ... 02/02/06 - 20060024323 - Active immunization using a siderophore receptor protein The invention provides a vaccine for immunizing poultry and other animals against infection by a gram-negative bacteria, and a method of immunizing an animal using the vaccine. The vaccine may contain purified siderophore receptor proteins derived from a single strain or species of gram-negative bacteria or other organism, which are ... 02/02/06 - 20060024322 - Novel prophylactics/remedies for immunopathy A prophylactic/remedy for immunopathy for immunopathy comprising, as an active ingredient, modifications of Staphylococcal enterotoxin B (SEB) with substitution of at least one amino acid residues within the amino acid sequence of natural type SEB, or derivatives thereof, wherein the SEB modifications or derivatives thereof have inhibitory activity on T ... 01/26/06 - 20060018920 - Lawsonia derived gene and related omph polypeptides, peptides and proteins and their uses The present invention relates generally to therapeutic compositions for the treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by Lawsonia intracellularis or similar or otherwise related microorganism. In particular, the present invention provides a novel gene derived from Lawsonia intracellularis which encodes an immunogenic ... 01/26/06 - 20060018919 - Peptide mimotopes of lipooligosaccharide from nontypeable haemophilus influenzae as vaccines The present invention relates to peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccines. ... 01/12/06 - 20060008466 - Methods for treating and preventing microbial infections Methods for the treatment and prevention of microbial infection, such as infections caused by bacteria, viruses, fungi and parasites are disclosed, as are adjuvants for use with vaccines against such microbes. The methods use porcine β-defensins, such as porcine β-defensin-1 and are particularly useful for treating or preventing infections caused ... 01/05/06 - 20060002953 - Molecular differences between species of the m. tuberculosis complex Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb ... 12/29/05 - 20050287165 - Meningococcal antigens The invention provides proteins from Neisseria meningitidis (strains A & B), including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. ... 12/29/05 - 20050287164 - Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from Staphylococcus aureus, including the active fragments proteins from its fibrinogen binding domain such as Clf40 protein, the Clf33 protein, or ClfA N3, are provided which can ... 12/29/05 - 20050287163 - Mycoplasma polypeptides The invention provides methods and materials related to mycoplasma. For example, the invention provides mycoplasma polypeptides having the ability to increase calcium release from cells (e.g., porcine ciliated tracheal cells) as well as antibodies that bind to such mycoplasma polypeptides. In addition, the invention provides methods for identifying inhibitors of ... 12/22/05 - 20050281837 - Immunologically active peptides with altered toxicity useful for the preparation of antipertussis vaccine Immunologically active polypeptides with no or reduced toxicity useful for the preparation of an antipertussis vaccine. Method for the preparation of said polypeptides which comprises, cultivating a microorganisms transformed with a hybrid plasmid including the gene/s which codes for at least one of said polypeptides in a suitable medium and ... 12/15/05 - 20050276814 - Streptococcus pneumoniae proteins and nucleic acid molecules Novel protein antigens from Streptococcus pneumoniae are disclosed, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described. ... 12/08/05 - 20050271682 - Recombinant constructs of borrelia burgdorferi Novel chimeric nucleic acids, encoding chimeric Borrelia proteins comprising OspC or an antigenic fragment thereof and OspA or an antigenic fragment thereof, are disclosed. Chimeric proteins encoded by the nucleic acid sequences are also disclosed. The chimeric proteins are useful as vaccine immunogens against Lyme borreliosis, as well as for ... 12/08/05 - 20050271681 - Isolated frpb nucleic acid molecule and vaccine The present invention provides an isolated nucleic acid molecule that encodes an aminoacid sequence comprising a FrpB protein. The invention also provides vaccine compositions capable of protecting a mammal against infection by N. gonorrhoeae or N. meningitidis comprising the FrpB protein encoded by the isolated nucleic acid of the invention ... 12/08/05 - 20050271680 - Novel immunogenic proteins of leptospira The invention provides novel immunogenic proteins LigA and LigB from Leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits. ... 12/08/05 - 20050271679 - Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for ... 12/01/05 - 20050266016 - Porin b (porb) as a therapeutic target for prevention and treatment of infection by chlamydia The present invention features the use of PorB polypeptide as a therapeutic agent. In specific embodiment the invention features a chlamydial vaccine based on a PorB polypeptide, as well as methods for induction of a protective immune response against infection by Chlamydia and Chlamydiophila. The invention further features methods for ... 11/24/05 - 20050260223 - Salmonella vaccine materials and methods Attenuated mutant Salmonella bacteria containing inactivated virulence genes are provided for use in safe efficacious vaccines. ... 11/24/05 - 20050260222 - Structure-based receptor mimics targeted against bacterial superantigen toxins The invention provides therapeutic compositions useful in the treatment of bacterial superantigen mediated conditions, such as Toxic Shock Syndrome. The compositions comprise genetically engineered bifunctional polypeptides containing a specific T-cell receptor binding domain and a specific MHC class 11 receptor binding domain, each targeting non-overlapping epitopes on a superantigen molecule ... 11/17/05 - 20050255125 - Streptococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine The present invention relates to nucleic acid sequences encoding a 22.5 kD Streptococcus uberis protein and to parts of such nucleic acid sequences that encode an immunogenic fragment of such proteins, and to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or ... 11/10/05 - 20050249749 - B-cell epitopes in the n-terminal repeated peptides of anaplasma marginale major surface protein 1a, pharmaceutical compositions and methods of use B-cell epitopes in the N-terminal repeated peptides of Anaplasma marginale major surface protein (MSP)1a are characterized. Pharmaceutical compositions including such epitopes, and methods useful to induce or enhance an immune response against infection by ehrlichial parasites of the species Anaplasma marginale, are provided. ... 11/10/05 - 20050249748 - Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof The present invention provides recombinant nucleic acid molecules, expression cassettes, and vectors useful for expression of polypeptides, including heterologous polypeptides, such as antigens, in bacteria. Some of the recombinant nucleic acid molecules, expression cassettes and vectors comprise codon-optimized sequences encoding the polypeptides and/or signal peptides. Some of the recombinant nucleic ... 11/10/05 - 20050249747 - Recombinant high molecular weight major outer membrane protein of moraxella An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided by recombinant means. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic ... 11/10/05 - 20050249746 - Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity A P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable H. influenzae (NTHi) is useful as an active component in an immunogenic composition for humans. Methods of using these proteins, and compositions containing them in combination ... 11/03/05 - 20050244425 - Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability The present invention describes the isolation and purification of histidine-tagged functional portions of intimin (his-tagged intimin or his-intimin), a protein associated with the ability of certain strains of pathogenic bacteria to adhere to epithelial cells. The invention further describes the use of intimin as an antigen to promote a protective ... 10/20/05 - 20050232943 - Antigenic composition of a pseudomonas aeruginosa protein A novel antigen from P. aeruginosa is provided. The use of the antigen in detecting/diagnosing P. aeruginosa as well as its use in eliciting an immune response are also provided. ... 10/20/05 - 20050232942 - Virulence genes, proteins, and their use A series of genes from Streptococcus pyogenes are shown to encode products which are implicated in virulence. The identification of these genes therefore allows attuated microorganisms to be produced. Furthermore, the genes or their encoded products can be used in the manufacture of vaccines for therapeutic application. ... 10/20/05 - 20050232941 - Compounds and methods for treatment and diagnosis of chlamydial infection Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with ... 10/20/05 - 20050232940 - Recombinant plasmid and a method of controlling the effects of yersinia pestis Described is a plasmid prepared by recombinant techniques which is used to prepare a vaccine against Y. pestis. ... 10/20/05 - 20050232939 - Novel therapeutic compositions for treating infection by lawsonia spp. The present invention relates generally to therapeutic compositions for the treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by Lawsonia intracellularis or similar or otherwise related microorganism. In particular, the present invention provides a novel gene derived from Lawsonia intracellularis, which encodes an immunogenic ... 10/20/05 - 20050232938 - Recombinant dna, plasmid, transformed microorganism and vaccine protein for prevention and therapy of urinary tract infection Disclosed is a novel vaccine against Escherichia coli (E. coli) responsible for urinary tract infections. The vaccine is a recombinant chimeric protein which is prepared by linking by genetic recombination a gene encoding an antigenic determinant of uropathogenic E. coli to a CTXA2B gene encoding nontoxic A2 and B subunits ... 10/20/05 - 20050232937 - Paramycobacterial diagnostics and vaccines The present invention relates to nucleic acid sequences encoding Mycobacterium avium subspecies paratuberculosis proteins, to parts of such nucleic acid sequences that encode an immunogenic fragment of such proteins, to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof. ... 10/20/05 - 20050232936 - Meningococcus adhesins nada, app and orf 40 NadA, App and ORF40 function as adhesins in N. meningitidis. Adhesion can be modulated by targeting these three proteins. NadA allelic variants are disclosed. Autoproteolytic cleavage of App is disclosed, as is removal of the activity by mutagenesis. App is processed and secreted into culture medium when expressed in E. ... 10/13/05 - 20050226891 - Multiple antigenic peptides immunogenic against streptococcus pneumonia The invention provides a nucleic acid encoding the 37-kDa pneumococcal surface adhesion A protein (PsaA) from Streptococcus pneumoniae. Also provided are isolated nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. The invention also provides purified polypeptides encoded by the nucleic acid encoding the ... 10/06/05 - 20050220809 - Nucleotide sequence coding for a tolc and a defined amino acid sequence The invention relates to a nucleotide sequence coding for a TolC and a defined amino acid sequence, said defined amino acid sequence being inserted in the permissive, membrane-external area of the TolC, and several uses thereof, particularly bacteria containing such a nucleotide sequence. ... 10/06/05 - 20050220808 - Peptide vaccines against group a streptococci This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can ... 10/06/05 - 20050220807 - Methods of delivery of exogenous proteins to the cytosol and uses thereof The present invention is directed to a method for delivering exogenous proteins to the cytosol, by binding a target antigen (such as a protein) to a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferably, the target antigen is fused to ... 09/29/05 - 20050214320 - Compositions isolated from m. vaccae and their use in the modulation of immune responses Polypeptides and polynucleotides isolated from Mycobacterium vaccae are provided, together with compositions comprising such polypeptides and polynucleotides, and methods for their use in the enhancement of immune responses to heterologous antigens. ... 09/22/05 - 20050208069 - Polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate in which the amino acid sequence is set forth in any of SEQ ID NOS: 1, 3-7, or 9-11, including fragments, mutants, variants, analogs, or derivatives, thereof. Also, this invention provides ... 09/15/05 - 20050202037 - Group a streptococcal vaccines The present invention provides methods for eliciting an immune response against Group A streptococci, comprising use of recombinant fusion polypeptides, and compositions thereof, that include a multivalent immunogenic portion of at least two immunogenic polypeptides from Group A streptococci M proteins (which are capable of stimulating a protective immune response ... 09/08/05 - 20050196408 - Method of administering fimh protein as a vaccine for urinary tract infections The present invention relates to methods of stimulating an immune response in a primate utilizing compositions comprising bacterial adhesin proteins and/or immunogenic fragments thereof. The compositions are useful for the prevention and treatment of bacterial induced diseases involving bacterial adherence to a target cell, such as diseases of the urinary ... 09/08/05 - 20050196407 - Receptor for b. anthracis toxin The present invention relates to mammalian anthrax toxin receptor polypeptides and polynucleotides encoding same as well as related polypeptides and polynucleotides, vectors containing the polynucleotides and polypeptides, host cells containing related polynucleotide molecules, and cells displaying no anthrax toxin receptor on an exterior surface of the cells—minus cell lines and ... 09/08/05 - 20050196406 - Polypeptide display libraries and methods of making and using thereof Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression ... 09/08/05 - 20050196405 - Pneumococcal surface protein c (pspc), epitopic regions and strain selection thereof, and uses therefor Disclosed and claimed are: epitopic regions of Pneumococcal Surface Protein C or “PspC”, different clades of PspC, isolated and/or purified nucleic acid molecules such as DNA encoding a fragment or portion of PspC such as an epitopic region of PspC or at least one epitope of PspC, uses for such ... 09/01/05 - 20050191316 - Neisseria genomic sequences and methods of their use The invention provides methods of obtaining immunogenic proteins from genomic sequences including Neisseria, including the amino acid sequences and the corresponding nucleotide sequences, as well as the genomic sequence of Neisseria meningitidis B. The proteins so obtained are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. ... 09/01/05 - 20050191315 - Identification of epitopes on staphylococcal enterotoxins The present invention relates to novel peptides that inhibit transcytosis of Staphylococcal enterotoxins and methods for preventing and/or treating Staphylococcal enterotoxin-mediated diseases or conditions. ... 08/25/05 - 20050186218 - Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography The present invention relates to the purification of polypeptides and the removal of endotoxin via immobilized metal affinity chromatography (IMAC). More specifically, the invention relates to methods for removing bacterial endotoxin in a protein solution. In specific embodiments, the invention relates to the elimination of endotoxin from Moraxella catarrhalis outer ... 08/25/05 - 20050186217 - Compositions produced using enteric pathogens and methods of use The present invention provides compositions including polypeptides having the characteristics of polypeptides expressed by a reference microbe such E. coli or Salmonella. Examples of Salmonella strains that can be used include, for instance, S. enterica serovar Newport, S. enterica serovar Enteritidis, S. enterica serovar Typhimurium, and S. enterica serovar Dublin. ... 08/18/05 - 20050180987 - Method of separating protective components of bordetella pertussis To provide a method of efficiently separate protective components of Bordetella pertussis. On the basis of differences in adsorbability to calcium phosphate gel formed by adding calcium ions to a Bordetella pertussis culture in the presence of excess phosphate ions, protective components of Bordetella pertussis are separated from the Bordetella ... 08/18/05 - 20050180986 - Collagen-binding proteins from enterococcal bacteria A collagen-binding MSCRAMM entitled Ace from enterococcal bacteria is provided which was homologous to the ligand-binding region of Cna, the collagen-binding MSCRAMM from Staphylococcus aureus, and which can be utilized to inhibit adhesion of enterococcal bacteria to extracellular matrix proteins. The N-terminal region of Ace contained a region (residues 174-319), ... 08/18/05 - 20050180985 - Live attenuated salmonella strains for producing monovalent or multivalent vaccines Disclosed herein methods for producing live attenuated Salmonella typhi, Salmonella paratyphi A and B and other Salmonella mutants which can be used in vaccines to prevent diseases caused by Salmonella infection. These mutants can also be used to prevent or treat diseases caused by other bacterial strains, by viral and ... 08/04/05 - 20050169937 - Attaching substances to microorganisms The invention relates to surface display of proteins on microorganisms via the targeting and anchoring of heterologous proteins to the outer surface of cells such as yeast, fungi, mammalian, plant cells, and bacteria. The invention provides a proteinaceous substance comprising a reactive group and at least one attaching peptide including ... 07/21/05 - 20050158335 - Haemophilus influenzae type iv pili The invention described herein relates to a Haemophilus influenzae (H. influenzae) regulon encoding type IV pili. In particular, the invention relates to type IV pili from nontypeable H. influenzae (NTHi) and from H. influenzae strains a, b, c, e and f. The invention provides isolated H. influenzae pilus polynucleotides and ... 07/21/05 - 20050158334 - Vaccines comprising aluminium adjuvants and histidine To improve the stability of vaccines comprising aluminum salt(s), the invention uses the amino acid histidine. This can improve pH stability and adjuvant adsorption and can be reduce antigen hydrolysis. Histidine is preferably presen during adsorption to the aluminium salt(s). The antigen in the vaccine may be a protein or ... 06/30/05 - 20050142146 - Chlamydia antigens and corresponding dna fragments and uses thereof The present invention provides a vaccine for immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The vaccine contains a polypeptide comprising an omp P6 precursor sequence of a strain of C. pneumoniae and variants of the sequence. Modifications are ... 06/30/05 - 20050142145 - Derivatives of choline binding proteins for vaccines The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species with pneumococcal derived polypeptides that include an alpha helix but exclude a choline binding region as a mechanism for stimulating production of ... 06/23/05 - 20050136070 - Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same Compositions comprising products of the csa operon, an isolated nucleic acid encoding the csa operon or functional fragments thereof, purified polypeptide products of the csa operon or functional fragments thereof, methods of eliciting an immune response to these products, and methods of producing products of the csa operon are disclosed ... 06/23/05 - 20050136069 - Compounds and methods for immunotherapy and diagnosis of tuberculosis Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M. ... 06/23/05 - 20050136068 - Streptococcal c5a peptidase vaccine Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, ... 06/16/05 - 20050129706 - Modified arginine deiminase The present invention is directed to arginine deiminase modified with polyethylene glycol, to methods of treating cancer, and to methods of treating and/or inhibiting metastasis. ... 06/02/05 - 20050118190 - Staphylococcus antigen and vaccine A negatively-charged Staphylococcus antigen contains amino acids and a N-acetylated hexosamine as a major carbohydrate component. The antigen is common to many coagulase-negative strains of Staphylococcus, including S. epidermidis, S. haemolyticus, and S. hominis. Staphylococcus strains that carry the antigen include many clinically significant strains of Staphylococcus. The antigen and ... 06/02/05 - 20050118189 - Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease A multi-component immunogenic composition confers protection on an immunized host against infection caused by Haemophilus influenzae. Such composition comprises at least two different antigens of Haemophilus influenzae, one of which is an adhesin. High molecular weight (HMW) proteins of non-typeable Haemophilus influenzae enhance the immune response in a host to ... ### FreshPatents.com Support |